The NMPA Accepts Everest Medicine's IND Application for Zetomipzomib to Treat Immune Mediated Disorders
Shots:
- Everest Medicines's IND application for zetomipzomib was accepted by China's NMPA for the treatment of patients with immune-mediated disorders, incl. lupus nephritis (LN)
- Earlier the result of the P-II study at 25 & 37 week showed an overall renal response rate of 64.7% & 88.2%, the mean reduction in UPCR from baseline was 57.0% & 83.0% while eGFR remained stable during treatment. Additionally, it also showed a favorable safety & tolerability profile
- Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor. Everest Medicines, in collaboration with Kezar Life Sciences, is set to participate in the P-IIb (PALIZADE) trial
Ref: PR Newswire | Image: Everest Medicines
Related News:- Kezar Life Sciences Entered into a Collaboration and License Agreement with Everest Medicines for Zetomipzomib to Treat Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
